With the increasing frequency of haploidentical transplantation, it is becoming more important to establish the degree of HLA mismatch that can be accepted. We retrospectively analyzed clinical data of 50 adult Japanese patients with high-risk hematologic malignancies who underwent allogeneic peripheral blood stem cell transplantation (PBSCT) from two-or three-loci-mismatched related donors with HLA class I and II gene disparities in the graft-versus-host direction. They were treated at 20 transplant centers between 1996 and 2002. In all, 18 patients received unmanipulated PBSC, while 32 received purified CD34 þ blood cells. Conventional (n ¼ 31) or reduced-intensity (n ¼ 19) conditioning regimens were used. Of the 39 patients (78%) who survived for X28 days after transplant, 37 (95%) achieved neutrophil engraftment, while graft failure and rejection occurred in two of 39 (5%) and three of 37 (8%) patients, respectively. Stepwise Cox regression analysis revealed a significantly lower incidence of grades II-IV acute GVHD in patients receiving purified CD34 þ cells (hazard ratio 0.32; 95% CI 0.12-0.84; P ¼ 0.022). By 1 year post transplant, 28 patients (56%) had died of transplantrelated problems, including infectious complications (30%). Although the number of patients is small, our data suggest that transplant-related problems, particularly infectious complications, are major obstacles to the success of this therapy.
Summary:
With the increasing frequency of haploidentical transplantation, it is becoming more important to establish the degree of HLA mismatch that can be accepted. We retrospectively analyzed clinical data of 50 adult Japanese patients with high-risk hematologic malignancies who underwent allogeneic peripheral blood stem cell transplantation (PBSCT) from two-or three-loci-mismatched related donors with HLA class I and II gene disparities in the graft-versus-host direction. They were treated at 20 transplant centers between 1996 and 2002. In all, 18 patients received unmanipulated PBSC, while 32 received purified CD34 þ blood cells. Conventional (n ¼ 31) or reduced-intensity (n ¼ 19) conditioning regimens were used. Of the 39 patients (78%) who survived for X28 days after transplant, 37 (95%) achieved neutrophil engraftment, while graft failure and rejection occurred in two of 39 (5%) and three of 37 (8%) patients, respectively. Stepwise Cox regression analysis revealed a significantly lower incidence of grades II-IV acute GVHD in patients receiving purified CD34 þ cells (hazard ratio 0.32; 95% CI 0.12-0.84; P ¼ 0.022). By 1 year post transplant, 28 patients (56%) had died of transplantrelated problems, including infectious complications (30%). Although the number of patients is small, our data suggest that transplant-related problems, particularly infectious complications, are major obstacles to the success of this therapy. Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative therapeutic approach for a number of life-threatening hematologic malignancies. 1 Unfortunately, only 30-40% of patients have a matched related donor (MRD) or a one-locus-mismatched related donor (MMRD), mismatched for either HLA-A, -B or -DR antigens, availabe. 2 Therefore, most transplant centers perform allogeneic HSCT from a matched unrelated donor (MUD) as a second option for those who do not have an MRD. Even though a large number of volunteers are willing to donate bone marrow, there are candidate patients for whom an MUD is not available. Moreover, the aggressive nature of their diseases often precludes a lengthy search for an MUD. Recently, unrelated cord blood (CB) has been used as a source of allogeneic HSCT. 3 However, in some cases, it is difficult to collect a sufficient number of stem cells from CB to engraft adult patients, which has been reported as an important factor of improved event-free survival. 4 Therefore, two-or three-loci-MMRD, which are readily available, have been proposed as a potential stem cell source.
The degree of HLA disparity between patients and donors has been reported to have a major impact on the outcome of allogeneic HSCT, particularly on engraftment and acute GVHD. 5, 6 Although the incidence of graft failure in BMT from a three-loci-MMRD or a haploidentical related donor has been reported to be higher than in BMT from a one-locus-or two-loci-MMRD, 7 allogeneic HSCT from a two-or three-loci-MMRD was demonstrated to be feasible for the achievement of stable engraftment. 8 Allogeneic HSCT from a two-loci-MMRD was reported to be associated with a similar incidence and severity of acute GVHD as conventional allogeneic HSCT from a onelocus-MMRD, 9 especially in patients receiving purified CD34 þ blood cells. 10 It is becoming more important to establish the degree of HLA mismatch that can be accepted.
The Japanese population is believed to be relatively homogeneous both ethnically and genetically, with less HLA genetic diversity than Caucasians. 11, 12 This could make unmanipulated allogeneic HSCT between two-or three-loci-mismatched pairs more feasible in this population because there may be lower incidence of graft failure and GVHD. Allogeneic peripheral blood stem cell transplantation (PBSCT) is increasingly undertaken in Japan since it became eligible for reimbursement from health insurance in the year 2000. We conducted a nationwide retrospective survey to investigate the time course of engraftment, incidence of acute and chronic GVHD, transplant-related problems and survival in patients undergoing allogeneic PBSCT from two-or three-loci-MMRD with HLA class I (HLA-A and/or -B) and II (HLA-DRB1) gene disparities in the graft-versus-host (GVH) direction.
Patients and methods

Patient characteristics
This study included 50 Japanese patients over age 16 who underwent allogeneic PBSCT from two-or three-loci-MMRD with HLA class I (HLA-A and/or -B) and II (HLA-DRB1) gene disparities in the GVH direction for a variety of high-risk hematologic malignancies. They were transplanted between January 1996 and March 2002 at 20 different transplant centers in Japan. The patients consisted of 17 (34%) with AML, six (12%) with ALL, six (12%) with myelodysplastic syndrome (MDS), eight (16%) with CML, 11 (22%) with non-Hodgkin's lymphoma (NHL) and two (4%) with multiple myeloma (MM). All of them were considered to be at high risk for relapse or to be refractory to intensive chemotherapy: 18 patients (36%) were transplanted at primary refractory status, 17 (34%) at chemorefractory status, nine (18%) in relapse after prior autologous PBSCT, three (6%) in relapse after prior allogeneic BMT from an MUD (MUD-BMT), one (2%) in relapse after prior unrelated CB transplantation and MUD-BMT, and two (4%) after graft rejection following MUD-BMT for MDS. A total of 33 patients (66%) underwent primary allogeneic PBSCT and 17 (34%) underwent allogeneic PBSCT after prior autologous PBSCT (n ¼ 10, 20%) or prior allogeneic HSCT (n ¼ 7, 14%). The median time interval between prior autologous PBSCT or allogeneic HSCT and this therapy was 10.8 (range 3.1-27.3) or 5.3 months (1.7-29.2 months), respectively. Patient characteristics are summarized in Table 1 . Treatment protocols were approved by local institutional review boards and all patients provided informed consent.
Stem cell collection and graft manipulation
G-CSF (Filgrastim, Kirin Brewery/Sankyo Co., Tokyo, Japan) was administered subcutaneously to donors at a dose of 400 mg/m 2 per day for 4 or 5 days as previously reported. 13 Leukaphereses were performed using a continuous-flow blood cell separator (Cobe Spectra, Cobe Laboratories, Lakewood, CO, USA) for 1-3 days beginning on day 4 of G-CSF administration until 3.0 Â 10 6 CD34 cells/kg (patient body weight) had been collected. The percentages of CD34 þ and CD3 þ cells in the graft were determined by flow cytometry. Median doses of nucleated, CD34 þ and CD3 þ cells infused are shown in Table 1 . Immunomagnetic selection was performed using a CliniMACS device (n ¼ 17; Kirin Brewery, Tokyo, Japan) 14 or an Isolex system (n ¼ 15; Baxter, Munich, Germany) 15 according to the manufacturer's recommendations. The graft was cryopreserved until infusion as previously reported. 16 
Conditioning regimen and GVHD prophylaxis
A conventional conditioning regimen was administered to 31 patients (62%). In all, 26 (52%) received 8-13.2 Gy TBI, and eight (16%) were given antithymocyte globulin (ATG) as an additional immunosuppressive. All patients treated with a conventional conditioning regimen received GVHD prophylaxis (CYA-based, n ¼ 18; FK506-based, n ¼ 13), as summarized in Table 2. A total of 19 patients (38%) were treated with a reducedintensity conditioning regimen: eight (16%) received 2-6 Gy TBI and 11 (22%) were given ATG. All but one of these patients treated with a reduced-intensity conditioning regimen received GVHD prophylaxis (CYA-based, n ¼ 8; FK506-based, n ¼ 9; prednisolone alone, n ¼ 1).
Definition of outcome
Neutrophil engraftment was defined as an absolute neutrophil count (ANC) exceeding 0.5 Â 10 9 /l for 3 consecutive days after transplant. The day of neutrophil engraftment was determined to be the first of these 3 consecutive days. Platelet engraftment was defined as a platelet count exceeding 20 Â 10 9 /l without platelet support. In all 42 patients (84%) received G-CSF until neutrophil engraftment after transplant. If the ANC never exceeded 0.5 Â 10 9 /l or if it was not maintained above 0.5 Â 10 9 /l for at least 3 consecutive days by day 28 post transplant, the patient was considered to have 'graft failure'. If ANC of greater than 0.5 Â 10 9 /l could not be maintained after initial engraftment, the patient was considered to have 'graft rejection'.
The severity of acute GVHD was graded according to the consensus criteria 17 among 43 evaluated patients (86%) who developed acute GVHD within 28 days or who survived X28 days after transplant. Chronic GVHD was assessed and graded according to the standard criteria 18 Allogeneic PBSCT from two-or three-loci-MMRD S Yamasaki et al among 25 patients with sustained engraftment for X100 days after transplant. Regimen-related toxicity (RRT) of organ systems before day 100 post transplant was graded according to the criteria proposed by Bearman et al. 19 A clinical diagnosis of veno-occlusive disease (VOD) was made based on the presence of jaundice (bilirubin X2 mg/dl), hepatomegaly and/or right upper quadrant pain, and X5% weight gain from admission, with or without ascites. 20 The diagnosis of thrombotic microangiopathy (TMA) was made if the patient had thrombocytopenia (defined as a platelet count o100 Â 10 9 /l), microangiopathic hemolytic anemia as indicated by red blood cell fragmentation present in a peripheral blood smear and elevated lactate dehydrogenase (LDH), without an identifiable cause for the thrombocytopenia or microangiopathic hemolytic anemia (eg, sepsis, disseminated intravascular coagulation, carcinoma, eclampsia). 21 Relapse was defined either by morphologic evidence of the disease in the peripheral blood, marrow or extramedullary sites, or by recurrence and sustained presence of pretransplant chromosomal abnormalities in cytogenetic analysis of the marrow cells. Patients with CML, in whom the sole evidence of the disease was positivity for the bcr/ abl RNA transcript by polymerase chain reaction, were not classified as having relapse. Both relapse and progression were defined as disease progression with transplant-related deaths being censored. Treatment-related mortality (TRM) c The dose of CD34+ cells was significantly higher in patients receiving CD34+ blood cells purified by a CliniMACS device than in those receiving unmanipulated PBSC (P ¼ 0.0027) or CD34+ blood cells purified by an Isolex system (P ¼ 0.014). The dose of CD3+ cells was significantly higher in patients receiving unmanipulated PBSC than in those receiving CD34+ blood cells purified by a CliniMACS device (P ¼ 0.0004) or an Isolex system (P ¼ 0.0009).GVH, graft-versus-host; HVG, host-versus-graft; MDS, myelodysplastic syndrome; NHL, non-Hodgkin's lymphoma; MM, multiple myeloma; ECOG PS, Eastern Cooperative Oncology Group performance score.
Allogeneic PBSCT from two-or three-loci-MMRD S Yamasaki et al was defined as death from any cause other than relapse or disease progression. Progression-free survival (PFS) was defined as the time interval from transplant to the first event including relapse, disease progression and death. Overall survival (OS) was defined as the time interval from transplantation to death.
Data collection
Questionnaires were returned by 216 of 432 (50%) transplant centers in Japan. A total of 91 adult patients underwent allogeneic HSCT from a genotyped related donor mismatched at two or three loci in the GVH direction for the treatment of hematologic malignancies in a total of 32 centers (listed in the Appendix). 22 These data were collected from medical records. Histocompatibility was determined by serology for HLA-A, -B and -DR antigens and/or by DNA typing for HLA-A, -B and -DRB1. All of these HLA data were reviewed, and inquiries concerning patient and donor HLA typings were verified by the central committee. Of these 91 patients, 24 were excluded because they received BM, five because they were thought not to be at high risk for relapse or refractory to intensive chemotherapy, and six because their donors were not anticipated to be serological two-or three-loci-MMRD. As in allogeneic HSCT from related as well as unrelated donors, both HLA class I and II gene disparities contribute to increased incidence of graft failure or acute GVHD prophylaxis, 23, 24 identification of the fact that both HLA class I and II genes were disparate would be helpful. Thus, six patients were excluded because they received allogeneic PBSC from a two-or three-loci-MMRD with only HLA class I or II gene disparity in the GVH direction. Finally, we confirmed that 50 evaluable patients underwent allogeneic PBSCT from a two-or three-loci-MMRD with HLA class I (HLA-A and/or -B) and II (HLA-DRB1) gene disparities in the GVH direction for high-risk hematologic malignancies in 20 centers.
Statistical analysis
Comparisons of variables were performed using the twotailed Fisher exact test or the w 2 test. Continuous variables were compared by the Mann-Whitney U-test or the Kruskal-Wallis test. Competing risks for grades II-IV acute GVHD included death without grades II-IV acute GVHD, relapse, and graft failure and rejection. Relapse was a competing risk for TRM at day 100 post transplant, and TRM was a competing risk for relapse. The association of variables with the outcome was evaluated in multivariable analyses, with the use of stepwise Cox regression to adjust for differences in potentially confounding variables. [25] [26] [27] The variables considered were age and gender of patients or donors, number of transplantations, performance status (PS, which was evaluated before the start of the conditioning regimen and graded according to the Eastern Cooperative Oncology Group (ECOG) performance score), CD34 þ cell doses, degree of HLA genotypic disparity in the GVH direction, conditioning regimens including reduced regimens, TBI and ATG used, GVHD Table 2 Treatment characteristics
Conventional conditioning regimen 7 (39%) Allogeneic PBSCT from two-or three-loci-MMRD S Yamasaki et al prophylaxis and G-CSF used after transplant. Each of these factors was checked for the assumption of proportional hazards by using a time-dependent covariate. The interactions with outcomes, such as the incidence of neutrophil and platelet engraftment, complications including infection before day 100 post transplant, grades II-IV acute GVHD and TRM at day 100 post transplant, were assessed in a model that included these outcomes and the variables under consideration. Only factors significantly associated with the outcomes (Po0.05) were retained in the final models. End points were calculated on the day of the last patient contact. The outcomes PFS and OS following transplant were estimated by the Kaplan-Meier method and significance assessed by the log-rank test (Po0.05).
Results
Graft characteristics
The dose of CD34 þ cells given was significantly higher in patients who received CD34 þ blood cells purified by a CliniMACS device (CliniMACS-purified CD34 þ cells, n ¼ 17) than in those who received unmanipulated PBSC (n ¼ 18; P ¼ 0.0027) or CD34 þ blood cells purified by an Isolex system (Isolex-purified CD34 þ cells, n ¼ 15; P ¼ 0.014; Table 1 ). The target dose of CD34 þ cells (3.0 Â 10 6 CD34 cells/kg) was achieved in 36 donors (72%) by performing two or more leukaphereses. In all, 14 patients (28%) received o3.0 Â 10 6 CD34 cells/kg in unmanipulated PBSC (n ¼ 7), or CliniMACS-purified CD34 þ cells (n ¼ 1) or Isolex-purified CD34 þ cells (n ¼ 6). The dose of CD3 þ cells was also significantly higher in those receiving unmanipulated PBSC than in those receiving CliniMACS-or Isolex-purified CD34 þ cells (P ¼ 0.0004 or 0.0009, respectively). As the Isolex systems have changed over the years, variable CD34 þ cell doses from the Isolex system may be related to the use of earlier or later version of this equipment.
Engraftment
Among 39 patients (78%) who survived for X28 days after transplant, 37 (95%) and 25 (64%) achieved neutrophil and platelet engraftment, respectively. There was no significant difference in the number of days required for neutrophil engraftment between patients receiving unmanipulated PBSC (median 14 days, range 10-27 days), CliniMACSand Isolex-purified CD34 þ cells (14, 9-20 and 12, 9-20, respectively). There was also no significant difference in the number of days required for platelet engraftment between patients receiving unmanipulated PBSC (18.5, 0-46 days), and CliniMACS-and Isolex-purified CD34 þ cells (14, 9-23 and 16, 12-37, respectively).
A total of 11 patients (22%) died before 28 days (median 12 days range 3-27 days) post transplant without evidence of engraftment. Of these patients, two receiving o3.0 Â 10 6 CD34 cells/kg of unmanipulated PBSC or Isolex-purified CD34 þ cells died of RRT.
Graft failure and rejection
Graft failure occurred in two patients (5%). One of them had received CliniMACS-purified CD34 þ cells from a three-loci-MMRD, mismatched for HLA-A, -B and -DR antigens in the HVG direction, and was given a reducedintensity conditioning regimen containing ATG and GVHD prophylaxis with prednisolone. This patient developed grade IV pulmonary toxicity and died of pulmonary hemorrhage. The other patient with graft failure received Isolex-purified CD34 þ cells from a two-loci-MMRD, mismatched for HLA-B and -DR antigens in the HVG direction, and was given a conventional conditioning regimen containing ATG and GVHD prophylaxis with CYA plus prednisolone. This patient developed grade III stomatitis and gastrointenstinal toxicity and died of TMA after secondary allogeneic BMT. Additionally, they received purified CD34 þ cells mismatched for HLA-C antigen in the HVG direction.
Three patients (8%) developed graft rejection. All of them had received CliniMACS-purified CD34 þ cells and a conventional conditioning regimen including 12 Gy TBI without ATG. One patient received purified CD34 þ cells of o3.0 Â 10 6 CD34 cells/kg. Their donors were all mismatched for HLA-B and -DR antigens in the HVG direction, of whom two were also mismatched for HLA-C þ -A antigens in the HVG direction. They received GVHD prophylaxis with CYA plus methotrexate (n ¼ 2) or CYA alone (n ¼ 1).
GVHD
Grades II-IV acute GVHD developed in nine (64%) of 14 evaluable patients receiving unmanipulated PBSC, in three (20%) of 15 receiving CliniMACS-purified CD34 þ cells and five (36%) of 14 receiving Isolex-purified CD34 þ cells. By stepwise Cox regression analysis, the incidence of grades II-IV acute GVHD in patients receiving purified CD34 þ cells (28%) was significantly lower than in those receiving unmanipulated PBSC (64%) (hazard ratio (HR) 0.32; 95% confidence interval (CI) 0.12-0.84; P ¼ 0.022). While no patients receiving CliniMACS-(n ¼ 4) or Isolex-(n ¼ 7) purified CD34 þ blood cells with conditioning regimens containing ATG developed grade III or IV acute GVHD, four of 18 patients (22%) receiving CliniMACS-(n ¼ 11) or Isolex-(n ¼ 7) purified CD34 þ cells without ATG developed grade III or IV acute GVHD. Chronic GVHD developed in three of the 25 evaluable patients (12%; Table 3 ).
Regimen-related toxicity
Six patients (33%) of those receiving unmanipulated PBSC and 13 (41%) of those receiving purified CD34 þ cells developed RRT including grades II-IV organ toxicity before day 100 post transplant according to Bearman's criteria. Additionally, two patients (11%) and five (28%) of those receiving unmanipulated PBSC, and one (3%) and three (9%) of those receiving purified CD34 þ cells developed VOD or TMA, respectively (Table 3) . Seven of Allogeneic PBSCT from two-or three-loci-MMRD S Yamasaki et al 11 (64%) patients receiving unmanipulated PBSC and eight of 14 (57%) receiving purified CD34 þ cells died of RRT.
Infectious complications
By day 100 post transplant, the most serious treatmentrelated problem was some form of severe infectious complication, which was seen in 11 patients (61%) receiving unmanipulated PBSC, as follows: bacterial sepsis (n ¼ 8, 44%), bacterial pneumonia (n ¼ 3, 17%), fungal infection (n ¼ 2, 11%) including Candida (n ¼ 1) and others (n ¼ 1), and adenoviral disease (n ¼ 2, 11%). In 20 patients (63%) receiving purified CD34 þ cells, these figures were as follows: bacterial sepsis (n ¼ 12, 39%), bacterial pneumonia (n ¼ 2, 6%), fungal infection (n ¼ 10, 31%) including Aspergillus (n ¼ 2), Candida (n ¼ 1) and others (n ¼ 7), and viral disease (n ¼ 10, 31%) including CMV (n ¼ 5) and adenoviral (n ¼ 3) disease, and VZV reactivation (n ¼ 2).
Five of these 11 patients (45%) receiving unmanipulated PBSC and eight of these 20 (40%) receiving purified CD34 þ cells died of infectious complications before day 100 post transplant. Four of these five patients (80%) receiving unmanipulated PBSC and two of these eight (29%) receiving purified CD34 þ cells suffered from infectious complications before achieving neutrophil engraftment. Two patients, who developed grade IV acute GVHD and died of acute GVHD, suffered the complication of Candida infection or CMV disease, respectively, before day 100 post transplant (Table 4) .
Eight patients (16%) had carried over active infection to transplant. By day 100 post transplant, three patients who had bacterial infections (methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa or Stentrophomonas maltophilia) (infectious sites unknown) before the start of the conditioning regimen suffered sepsis, of whom one died of P. aeruginosa sepsis and one of adenoviral pneumonia after recovery from MRSA sepsis. One patient who had pneumonia of unknown origin died of bacterial sepsis, also of unknown origin. Two patients who had Candida liver abscesses or infections of unknown origin and site had Staphylococcus hemolyticus or bacterial sepsis of unknown origin, respectively (but recovered). One patient who had active chronic hepatitis C infection died of VOD. One patient who had Staphylococcus epidermidis tonsillitis had no infectious complications after transplantation.
Cause of death, relapse, disease progression and survival
In all 11 patients are surviving at a median of 11.7 months (range 4.4-35.5 months) and 39 patients died at a median time of 67 days (range 3-254 days) after transplant. The primary causes of death up to 1 year post transplant in 39 patients (78%) are listed in Table 5 . The most common cause of death was treatment-related problem, which was seen in 28 patients (56%). Of the 39 patients who survived X28 day after transplant with confirmed evidence of engraftment, two of 13 (15%) receiving unmanipulated PBSC and two of 26 (8%) receiving purified CD34 þ cells relapsed before day 100 post transplant.
Six patients were treated for relapse or disease progression with donor lymphocyte infusion (DLI), the median dose of CD3 þ cells being 9.6 Â 10 6 /kg (range 1.5 Â 10 5 -6.6 Â 10 7 /kg), and one underwent a third allogeneic PBSCT. Although grades II acute GVHD developed in two patients who received DLI, and grade III in one, there was no noticeable effect of DLI on disease progression.
Within 168 days after transplant, two of seven patients (29%) undergoing allogeneic PBSCT after prior allogeneic HSCT relapsed and received DLI. One of these two died of Table 3 Engraftment, GVHD and regimen-related toxicity relapse and the other died of interstitial pneumonia. However, five of the seven (71%) undergoing allogeneic PBSCT after prior allogeneic HSCT died of infectious complications. The probability of PFS at 1 year in patients undergoing primary allogeneic PBSCT (n ¼ 33) or allogeneic PBSCT after prior autologous PBSCT (n ¼ 10) was 25.4 and 20.0%, respectively. The probability of OS at 1 year in patients undergoing primary allogeneic PBSCT or allogeneic PBSCT after prior autologous PBSCT was 26.0 and 20.0%, respectively. None of the patients undergoing allogeneic PBSCT after prior allogeneic HSCT survived X196 days after transplant (Figure 1 ). There was no significant difference in the incidence of TRM at day 100 post transplant between patients receiving unmanipulated PBSC (n ¼ 18, 56%) and purified CD34 þ cells (n ¼ 32, 44%). The probability of PFS at 1 year in patients receiving unmanipulated PBSC or purified CD34 þ cells was 22.2 and 17.6%, respectively (P ¼ 0.63). The probability of OS at 1 year in patients receiving unmanipulated PBSC or purified CD34 þ cells was 26.7 and 17.9%, respectively (P ¼ 0.93; Figure 2 ). Table 5 Causes of death before 1 year post transplant
Relapse/progressive disease 2 (11%) 9 (28%) Treatment-related problem 11 (61%) 17 (53%) Infectious complication 5 (28%) 10 (31%) Organ toxicity a 5 (28%) 5 (16%) Acute GVHD+infectious complication 1 (5%) 2 (6%) a Organ toxicity ¼ pulmonary hemorrhage (n ¼ 2), VOD (n ¼ 2), TMA (n ¼ 2), interstitial pneumonia (n ¼ 2), intracerebral hemorrhage (n ¼ 1) and asphyxia due to oral hematoma (n ¼ 1). 
a Number of patients (number of deaths) is shown. b Others ¼ Rhodotorula rubra, Pneumocystis carinii or origin unknown. Neut, number of patients with incidence of infectious complications before achieving neutrophil engraftment; aGVHD, number of patients with incidence of infectious complications after treating grades II-IV acute GVHD with prednisolone; both, number of patients with incidence of infectious complications before achieving neutrophil engraftment (Neut) and after treating grades II-IV acute GVHD with prednisolone (aGVHD); CMV antigenemia, positive for CMV antigen without diseases caused by CMV infection. Allogeneic PBSCT after prior allogeneic HSCT (n = 7) Figure 1 Probability of OS for patients undergoing primary allogeneic PBSCT, and allogeneic PBSCT after prior autologous PBSCT and allogeneic HSCT. The probability of OS at 1 year in patients undergoing primary allogeneic PBSCT or allogeneic PBSCT (n ¼ 33, solid line) after prior autologous PBSCT (n ¼ 10, dashed line) was 26.0 and 20.0%, respectively. None of the patients undergoing allogeneic PBSCT after prior allogeneic HSCT (n ¼ 7, dotted line) survived X196 days after transplant.
Allogeneic PBSCT from two-or three-loci-MMRD S Yamasaki et al
There was no significant difference in the incidence of TRM at day 100 post transplant between patients receiving a conventional (n ¼ 31, 48%) and a reduced-intensity conditioning regimen (n ¼ 19, 47%). The probability of PFS at 1 year in patients receiving a conventional or a reduced-intensity conditioning regimen was 26.3 and 16.2%, respectively (P ¼ 0.86). The probability of OS at 1 year in patients receiving a conventional or a reducedintensity conditioning regimen was 26.3 and 17.0%, respectively (P ¼ 0.77).
Discussion
Our data support the notion that the present approach may be a possible option for a realistic alternative rescue for patients who lack an HLA-matched or a one-locusmismatched related or unrelated donor, because we found that a significant proportion of patients with high-risk hematologic malignancies survived this procedure. As expected, we found that graft manipulation reduced the incidence of grades II-IV acute GVHD. However, there was no significant difference between the probabilities of PFS and OS at 1 year in patients receiving unmanipulated PBSC and purified CD34 þ cells. We confirmed that transplant-related problems, particularly infectious complications, before day 100 post transplant were still major obstacles to the success of this therapy.
In the present analysis, we found that there were no significant differences in the time interval to neutrophil engraftment between patients receiving unmanipulated PBSC and purified CD34 þ cells. On the other hand, we found that all graft failures (5%, 2/39) and rejections (8%, 3/37) were observed in those receiving purified CD34 þ cells. We previously reported that in 13 Japanese children receiving purified CD34 þ cells from a partially MMRD, 28 the observed rates of graft failure and rejection were 31% (4/13) and 22% (2/9), respectively. Kato et al 29 analyzed the clinical course in 135 young Japanese patients who underwent allogeneic HSCT with purified CD34 þ cells from a haploidentical related donor, and found that graft failure occurred in 13% (13/103) of the patients with malignant diseases. Hence, the incidence of graft failure in the current study appears to be less than those in the previous Japanese reports. However, Aversa et al 30 reported that graft failure and rejection was 5% (2/43) and 0% (0/41), respectively. Recently, Redei et al 31 showed that all evaluable patients, who received X5 Â 10 6 CD34 þ blood cells purified by an Isolex system without cryopreservation, and were given a conditioning regimen including high-dose TBI, thiotepa, fludarabine and ATG without post transplant immunosuppressive treatment, established successful neutrophil engraftment. As we felt we were able to employ less immunosuppressive conditioning regimens to reduce transplant-related problems, we assumed that graft failure and rejection occurred at higher rates in our study than these two published studies. Additionally, in an attempt to reduce the risk of graft failure, various methods, including purification of blood cells to acquire very large numbers of CD34 þ cells, follow-up DLI or T-cell addback, and various types of anti-lymphocyte or thymocyte antibodies have been investigated, 27 ,32,33 but we could not find a benefit of employment of these well-established methods in our data. The explanation may again be that most patients were heavily pretreated prior to allogeneic PBSCT from two-or three-loci-MMRD . On the other hand, because all patients with graft failure and two of three of those with graft rejection had received purified CD34 þ cells mismatched for HLA-C antigen in the HVG direction, matching for this locus may be an important factor to prevent graft failure and rejection when using purified CD34 þ cells. The results of our study again highlight the notion that this approach with purified CD34 þ cells should be conducted in a well-designed larger study, focusing on the prevention of graft failure and rejection.
As expected, in this study, the incidence of grades II-IV acute GVHD was significantly lower in patients receiving purified CD34 þ cells (28%) compared with unmanipulated PBSC (64%). Similarly, several other studies reported that graft manipulation reduced the incidence of grades II-IV acute GVHD (range 0-21%). [29] [30] [31] As our patients received higher doses of CD3 þ cells contained in the Isolex-purified CD34 þ cells, or less immunosuppressive conditioning regimens with or without various kinds of GVHD prophylaxis, the incidence of grades II-IV acute GVHD in patients receiving purified CD34 þ cells may be higher in our study than in other studies. Nonetheless, overall, PFS and OS did not differ significantly between patients receiving unmanipulated PBSC and purified CD34 þ cells. This may have been due to the many transplant-related problems before day 100 post transplant observed with this approach. Ruggeri et al 34 showed that donor-versus-recipient natural killer (NK)-cell alloreactivity could protect patients against GVHD in allogeneic haploidentical HSCT. Procedures for purifying CD34 þ cells have recently been introduced for allogeneic PBSCT from two-or three-loci-MMRD with the development of the CliniMACS and Isolex systems. Although further studies are needed to determine whether cell separation approaches can be applied to this approach, our data suggest that technological advances in cell separation of Allogeneic PBSCT from two-or three-loci-MMRD S Yamasaki et al PBSC allografts may influence the incidence of acute GVHD. We could not find risk factors of RRT, VOD and TMA in pretransplant clinical status, such as PS and prior HSCT, in pretransplant treatment, such as conditioning regimens, or in post transplant treatment, such as GVHD prophylaxis and G-CSF use. Recently, new methods of transplantation, that is, nonmyeloablative pretransplant conditioning with or without ATG, 35 and improvements in supportive care in allogeneic HSCT, such as prevention and treatment of GVHD and infectious complications, have been introduced. However, none of the patients who underwent prior allogeneic HSCT survived X196 days after transplantation. Five of the seven (71%) undergoing allogeneic PBSCT after prior allogeneic HSCT died of infectious complications. These results emphasize that this approach after prior allogeneic HSCT should be conducted in a well-designed study, focusing on the prevention of infectious complications, regardless of the application of conventional or reduced-intensity conditioning regimens.
We found that the major cause of death was infectious complications before 1 year post transplant (30%, 15/50), as has also been reported in several other studies (range 33-83%). 7, [28] [29] [30] [31] In our study, 20 patients (40%) suffered from bacterial sepsis before day 100 post transplant and 12 (24%) suffered from bacterial sepsis before achieving neutrophil engraftment. Thus, the effective prevention and treatment of bacterial infection occurring early after transplantation, especially before achieving neutrophil engraftment, may be of primary importance for the success of this approach. Although Volpi et al 36 have shown that G-CSF promotes T-helper (Th)-2 immune deviation, which, unlike Th1 responses, does not protect against fungi, G-CSF after transplant may be useful to reduce the incidence of infectious complications, particularly bacterial ones, because of achieving early neutrophil engraftment. On the other hand, delayed reconstitution of T cells may cause a high incidence of infectious complications, especially fungal and viral infections. Handgretinger et al 37 suggested that the transplantation of higher doses of purified CD34 þ cells may hasten immune reconstitution. Thus, the number of transplanted CD34 þ cells may be important to prevent fungal and viral infections. Although post transplant therapy, such as DLI or T-cell add-back, and reduced GVHD prophylaxis or reduced in vivo T-cell depletion may increase the incidence of GVHD, they may reduce the incidence of fungal and viral infections. They should be further investigated in future prospective trials. The incidence of infectious complications was high (75%) in our patients with a carry-over infection before the start of the conditioning regimen. Thus, we should therefore consider selection of patients very carefully and may exclude those with a carry-over infection, particularly MRSA and multidrug-resistant P. aeruginosa, from eligibility in any future study.
Our study was limited by the inevitable bias associated with a small population of patients treated at 20 different centers. Nevertheless, we found that a small but significant proportion of patients with high-risk hematologic malignancies survived this approach. In Japan, Kawano et al 28 previously reported that the probability of PFS and OS at 1 year was 30 and 40%, respectively, and Kato et al 29 reported that the probability of PFS at 67 months was 5.7%. Aversa et al 30 reported that the probability of OS at 18 months was 28% (including seven (16%) of 43 standardrisk patients). The probability of OS at 2 years in a study reported by Redei et al 31 was 25%. Although this approach is not significantly better in Japan than elsewhere in contrast to allogeneic HSCT from MUD, our data also support the notion that this modality may be a possible option as a realistic alternative rescue for patients who lack an HLA-matched or a one-locus-mismatched related or unrelated donor, regardless of whether they received unmanipulated PBSC or purified CD34 þ cells, or the application of conventional or reduced-intensity conditioning regimens.
In conclusion, because only a small number of patients survived this procedure, future studies of allogeneic PBSCT with purified CD34 þ cells should be conducted on the prevention of graft failure and rejection, and the observed high risk of treatment-related problems requires eligibility criteria for the selection of patients and the effective prevention and treatment of infectious complications occurring early after transplant. Our data suggested that patients undergoing prior allogeneic HSCT and those with a carry-over infection before the start of the conditioning regimen should also be excluded from this approach because their mortality from infectious complications was extremely high, regardless of whether they received unmanipulated PBSC or purified CD34 þ cells, or the application of conventional or reduced-intensity conditioning regimens with or without various kinds of GVHD prophylaxis. The strategy for graft manipulation, and the application of conditioning regimens and GVHD prophylaxis should be further investigated in future prospective trials.
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